Conditions: Cancer
Keywords: Advanced solid tumours Advanced cancer tumor tumour RECENTIN
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 60
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether food has any effect on a single dose of Cediranib (AZD2171, Recentin™)followed by an assessment of the safety and tolerability of fixed daily dosing in comparison to varying dose levels on a patient-by-patient basis.

Detailed description:

Arms:
arm 1: Part A: Cediranib 45 mg Fed State arm 2: Part A: Cediranib 45 mg Fasted State arm 3: Part B: Cediranib 45 mg Fixed Dose arm 4: Part B: Cediranib 30 - 90 mg Dose Escalation

Interventions: intervention 1: Cediranib intervention 2: Cediranib 30 - 90 mg
Intervention descriptions: intervention 1: 45 mg oral dose intervention 2: oral tablet dose escalation

Protocol document: